Pfizer develops, manufactures, and sells prescription drugs and vaccines to patients worldwide, distributed through hospitals, pharmacies, and healthcare systems. Key products include the Prevnar pneumococcal vaccine, blood thinner Eliquis (co-marketed with Bristol-Myers Squibb), and heart drug Vyndamax. Revenue comes from product sales across more than 100 countries, split roughly 60% U.S. and 40% international, with emerging markets making up a meaningful share of the latter.
Employees81,000IPOAug 6, 2015SIC2834HQ66 Hudson Boulevard East, New York, NY, USA, 10001-2192
to
Financials
Profitability
Metric
Current
Margins
Gross Margin
74.3%
Operating Margin
27.8%
EBITDA Margin
26.8%
Net Margin
12.4%
OCF Margin
18.7%
FCF Margin
14.5%
Returns on Capital
ROE
8.7%
ROA
3.7%
ROIC
9.1%
ROCE
6.0%
ROC (Greenblatt)
54.4%
3Y ROIIC
−121.2%
Consistency
Years Profitable / 10Y
10
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
19.89
Forward P/E
9.08
P/E ex-NRI
8.33
Shiller P/E (CAPE)
9.64
Cash Flow Multiples
P/FCF
17.04
P/OCF
13.21
P/Owner Earnings
35.59
FCF Yield
5.90%
Enterprise Value Multiples
EV / EBIT
19.95
EV / Forward EBIT
10.16
EV / EBITDA
12.11
EV / Forward EBITDA
8.53
EV / Revenue
3.25
EV / Forward Revenue
3.34
Asset / Sales
P/S
2.47
P/B
1.78
P/Tangible Book
—
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
6.41%
Forward Dividend Yield
6.41%
3Y Dividend Growth
2.4%
Payout Ratio
0.53
5Y Yield on Cost
7.05%
Buybacks & Dilution
3Y Buyback Ratio
−0.40%
5Y Share Change
1.4%
Combined
Shareholder Yield
9.71%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
0.74
Gross Debt / EBITDA
3.81
Cash / Debt
0.21
Equity / Assets
0.42
Coverage
Interest Coverage
6.52
Short-Term Liquidity
Current Ratio
1.16
Quick Ratio
0.87
Cash Ratio
0.37
Composite Scores
Piotroski F-Score
6
Altman Z-Score
2.03
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-01-23
$0.43
2026-03-06
2025-11-07
$0.43
2025-12-01
2025-07-25
$0.43
2025-09-02
2025-05-09
$0.43
2025-06-13
2025-01-24
$0.43
2025-03-07
2024-11-08
$0.42
2024-12-02
2024-07-26
$0.42
2024-09-03
2024-05-09
$0.42
2024-06-14
2024-01-25
$0.42
2024-03-01
2023-11-09
$0.41
2023-12-04
10 of 22
View allDate
Transcript
Type
No transcripts found.
5-Step DuPont Analysis
ROE %
8.90%
×
×
Net Margin %
12.42%
×
×
Operating Margin %
27.81%
Operating Income
$17.41B
÷
Revenue
$62.58B
×
Tax Burden
1.0331
Net Income
$7.77B
÷
Pretax Income
$7.52B
×
Interest Burden
0.4321
Pretax Income
$7.52B
÷
Operating Income
$17.41B
×
Asset Turnover
0.30
÷
Revenue
$62.58B
÷
Average Total Assets
$210.78B
Begin Total Assets
$213.40B
End Total Assets
$208.16B
×
Equity Multiplier
2.41
÷
Avg Total Assets
$210.78B
÷
Avg Stockholders Equity
$87.34B
Begin Equity
$88.20B
End Equity
$86.48B